NCT04355520 2020-04-21
A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
Clinical Trials
1 trialsINDUSTRY × HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer × Fulvestrant × Clear all